MG
BIIB icon

Michael Gelband’s Biogen BIIB Stock Holding History

Michael Gelband’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$620K Sell
2,871
-149,122
-98% -$28.5M ﹤0.01% 1185
2026
Q1 		$27.9M Buy
+151,993
New +$28M 0.22% 58
2025
Q4 		– Sell
-31,931
Closed -$4.47M – 1556
2025
Q3 		$4.47M Sell
31,931
-97,560
-75% -$13.2M 0.05% 456
2025
Q2 		$16.3M Buy
129,491
+120,009
+1,266% +$15M 0.14% 138
2025
Q1 		$1.3M Buy
+9,482
New +$1.36M 0.01% 845
2024
Q4 		– Sell
-62,915
Closed -$12.2M – 1540
2024
Q3 		$12.2M Buy
62,915
+38,059
+153% +$7.96M 0.07% 205
2024
Q2 		$5.76M Buy
+24,856
New +$5.4M 0.04% 364
2023
Q4 		– Sell
-209,160
Closed -$53.8M – 1492
2023
Q3 		$53.8M Buy
209,160
+152,308
+268% +$40.7M 0.51% 29
2023
Q2 		$16.2M Sell
56,852
-47,444
-45% -$14.1M 0.13% 151
2023
Q1 		$29M Buy
104,296
+26,437
+34% +$7.32M 0.24% 60
2022
Q4 		$21.6M Buy
77,859
+27,298
+54% +$7.71M 0.31% 59
2022
Q3 		$13.5M Sell
50,561
-6,780
-12% -$1.44M 0.18% 140
2022
Q2 		$11.7M Buy
57,341
+24,791
+76% +$5.07M 0.14% 163
2022
Q1 		$6.86M Buy
32,550
+17,583
+117% +$3.82M 0.09% 294
2021
Q4 		$3.59M Buy
14,967
+1,107
+8% +$285K 0.04% 546
2021
Q3 		$3.92M Sell
13,860
-16,572
-54% -$5.43M 0.05% 481
2021
Q2 		$10.5M Buy
30,432
+27,445
+919% +$8.31M 0.12% 139
2021
Q1 		$836K Sell
2,987
-6,176
-67% -$1.67M 0.01% 1022
2020
Q4 		$2.24M Buy
9,163
+5,872
+178% +$1.51M 0.02% 500
2020
Q3 		$934K Sell
3,291
-20,365
-86% -$5.68M 0.02% 712
2020
Q2 		$6.33M Buy
+23,656
New +$7.11M 0.16% 118
2020
Q1 		– Sell
-918
Closed -$272K – 1095
2019
Q4 		$272K Sell
918
-35,919
-98% -$9.97M 0.01% 1193
2019
Q3 		$8.58M Buy
+36,837
New +$8.58M 0.3% 66

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's BIIB Position: Q2 2026 in Review

Michael Gelband reduced its Biogen (BIIB) stake by 98% in Q2 2026, selling an estimated $28.5M and leaving 2,871 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

Michael Gelband first reported a position in BIIB in Q3 2019 and has held it in 23 quarters since. The position peaked at $53.8M in Q3 2023. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Michael Gelband held 2,871 shares of Biogen worth $620K as of Q2 2026.
  • Michael Gelband sold 149,122 Biogen shares in Q2 2026, an estimated $28.5M.
  • Biogen made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1185 holding.
  • Michael Gelband first reported a position in Biogen in Q3 2019 and has held it in 23 quarters since.
  • Michael Gelband's Biogen position peaked at $53.8M in Q3 2023.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.